Feature | May 03, 2012 | Helen Kuhl

PET/CT: A Dynamic Duo

This article appeared as the introduction to a chart on PET/CT systems in the May 2012 issue.

Since it was named “Invention of the Year” by TIME magazine in 2000, positron emission tomography/computed tomography (PET/CT) has been hailed as a winning combination. It captures anatomical information from the CT and functional information from the PET to create a fused image at once, reducing some of the challenges that occur in fusing two images acquired at separate times from separate modalities.

Another benefit is having the attenuation correction provided by the CT.  “The quality of the images with attenuation depends on the accuracy of registration of the emission and transmission scan…Optimal correction for attenuation can be obtained using integrated PET/CT systems,” said Dominique Delbeke, M.D., Ph.D., Vanderbilt University Medical Center.1

Because it is so helpful to have CT in conjunction with PET, today virtually all PET units sold are hybrid devices. As noted by the National Oncologic PET Registry, most PET scans using either F-18 fluorodeoxyglucose (FDG) or sodium fluoride F-18 (NaF) as the tracer are done on a PET/CT hybrid.

Oncology, Cardiology and Other Uses
The complementary advantages offered by PET/CT are particularly useful in oncology. Tri-City PETCT, a diagnostic imaging facility in California, lists three main benefits to having a combined PET/CT scan: earlier diagnosis, accurate staging and localization, and precise treatment and monitoring.

Its website gives a few examples of how PET/CT can be used:

• Physicians can use it to differentiate between benign and malignant lesions;

• Surgeons can use it to determine the optimal location to perform an invasive procedure;

• Radiation oncologists can use it to tailor radiation fields reaching all the cancer cells without damaging the surrounding healthy cells;
• Medical oncologists can use PET/CT to monitor response to treatment.2

In addition, PET/CT has moved beyond oncology and is being used for coronary artery disease and in the diagnosis and evaluation of Alzheimer’s disease and other neurological conditions. The American College of Radiology, which offers courses in PET/CT three times a year, says in its course overview that PET/CT “has become the standard-of-care imaging modality in cancer management and has garnered an evolving role in diagnosing neurodegenerative and oncologic diseases.”3

Doing a combined PET/CT exam can be an advantage for the patient, who does just one exam instead of having to go to two different places for separate exams. And, since CT provides the attenuation correction, scan time is reduced, which also is easier for the patient.

However, PET/CT doesn’t come cheap, according to a Frost & Sullivan report released last year. It said, “Issues surrounding cost have restrained market progression. The cost of a PET/CT fusion scanner ranges anywhere between $1.9 million and $2.4 million, depending on the system configuration; however, this does not include the additional costs for extended interpretation times required by the radiologists.

“This is much larger than the cost of a stand-alone PET or CT scanner and, therefore, limits its availability in small medical imaging clinics and rural setups,”  the report continues. “This is because only multi-specialty hospitals and larger clinical setups can afford to install high-end hybrid systems.”4

New System Introductions
New PET/CT scanners were introduced by three major vendors in 2011:

• Introduced at the Radiological Society of North America (RSNA) 2011 show, the new Discovery PET/CT 710 from GE Healthcare features 128-slice imaging capabilities and Q.Suite, a collection of capabilities designed to extend quantitative PET by generating more consistent standardized uptake value (SUV) readings.

• Also at RSNA, Siemens Healthcare introduced the next-generation Biograph mCT PET/CT scanner that enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion). In mid-February, the U.S. Food and Drug Administration cleared features associated with the system.

• Philips Healthcare’s TruFlight Select PET/CT, introduced in mid-2011, is an economical system that incorporates the company’s Astonish TF time-of-flight (TOF) technology. TOF technology is designed to enhance image quality by reducing image artifacts and providing higher sensitivity. The resulting images help clinicians better detect and locate lesions to increase diagnostic confidence and preserve healthy tissue during treatment.

This article appeared as the introduction to a chart on PET/CT systems in the May 2012 issue.
 

References:
1 “Integrated FDG-PET and PET/CT: Clinical Applications and Impact on Patient Care,” courtesy of Dominique Delbeke, M.D., Ph.D., Vanderbilt University Medical Center through the PET PROS program of the SNM PET Center of Excellence
2 www.tricitypetct.com/patient.html#petct
3 www.acr.org/EducationCenter/ACRFutureClassroom/details-pet.aspx
4 “Technology Developments and Superior Diagnostic Capabilities Stoke Growth in the Hybrid Scanners Market,” Frost & Sullivan,
published March 22, 2011

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init